No Detail Found!

CD9 as a Potential Prognostic Biomarker in Paediatric B-Cell Acute Lymphoblastic Leukaemia

Author(s)
Fatima Meraj Department of Haematology, Indus Hospital and Health Network,Karachi,Pakistan
Neelum Mansoor Department of Cytogenetics, Indus Hospital and Health Network,Karachi,Pakistan
Omer Javed Department of Haematology, Indus Hospital and Health Network,Karachi,Pakistan
Saba Jamal Clinical Laboratories and Blood Transfusion Services, Indus Hospital and Health Network,Karachi,Pakistan
Abstract
Objective: To evaluate the role of CD9 for predictingETV6::RUNX1, BCR::ABL1, and KMT2A fusion genes with prognostic signi cance in B-cell acute lymphoblastic leukaemia (B-ALL). Study Design: An observational study. Place and Duration of the Study: Indus Hospital and Health Network, Karachi, Pakistan, from May 2020 to August 2022. Methodology: Data of 488 paediatric (B-ALL) children diagnosed by ow cytometry were retrieved. Recurrent genetic abnormalities for BCR::ABL1, ETV6::RUNX1, and KMT2A fusion genes were retrospectively monitored.Fisher s Exact, Pearson s Chi-Square, and Mann-Whitney U tests along with univariate and multivariate analyses were performed. Results: The frequency of BCR::ABL1 was 9.01% [p = 0.097]. The ETV6::RUNX1 gene rearrangement was observed in 37.0% vs. 52.6% (p = 0.168), and KMT2A gene rearrangement in 8.52% vs. 10.5% (p = 0.690) in CD9+ and CD9- groups, respectively. The potential signi cance ofBCR::ABL1 suggests CD9's role in indicating the presence of this unfavourable genetic marker, while for ETV6::RUNX1, CD9 expression may be linked to a less positive genetic pro le. Lymphadenopathywas signi cant in CD9+ group, while bone marrow blast counts were notable in CD9- group. The survival rates did not signi cantly di er between the two groups. Conclusion: CD9 can be used as a surrogate biomarker in predicting disease prognosis by recognising the patients with high-risk factors i.e., lymphadenopathy, elevated white blood cells, possible occurrence of BCR::ABL1, and the scarcity of ETV6::RUNX1 within the CD9+ group.
Publication Details
Page(s) 191-196
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 35, Issue: 2, Year: 2025

Request the full text from PASTIC

Keywords
prognostic marker, Cytogenetics, immunophenotyping, Gene rearrangement, CD9 expression
References
Howlader N,Noone A,Krapcho M,Garshell J,Miller D,Altekruse SF .1975 .National Cancer Institute. SEER cancer statistics review, : 2012.
Lejman M,Chalupnik A,Chilimoniuk Z,Dobosz M. .2022 .Genetic biomarkers and their clinical implications in B-cell acute lymphoblastic leukaemia in children. Int J Mol Sci, 10(5) : 2755.
Malard F,Mohty M. .2020 .Acute lymphoblastic leukaemia. Lancet, 6736(19) : 33018-1.
Tsagarakis NJ,Papadhimitriou SI,Pavlidis D,Marinakis T,Kostopoulos IV,Stiakaki E .2019 .Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B acute lymphoblastic leukaemia. Int J Lab Hematol, 10(3) : 364-72.
Qian M,Zhao X,Devidas M,Yang W,Gocho Y,Smith C .2019 .Genome-wide association study of susceptibility loci for T-cell acute lymphoblastic leukaemia in children. J Natl Cancer Inst, 10(12) : 1350-7.
Liang P,Miao M,Wang Z,Jiang H,Ma W,S W .2018 .CD9 expression indicates a poor outcome in acute lymphoblastic leukaemia. Cancer Biomark, 10(4) : 781-6.
Blunck CB,Granado ET,Noronha EP,Wajnberg G,Passetti F,de-Oliveira MSP .2018 .CD9 predicts ETV6-RUNX1 in childhood B-cell precursor acute lymphoblastic leukaemia. Hematol Transfus Cell Ther, 08(3) : 205-11.
Robert JH,Amoussou NG,Mai HL,Loge C,Brouard S C .2020 .Useful multifunction proteins for the possible design and development of small-molecule therapeutic tools. Drug Discov Today, 10(1) : 56-68.
Richardson MM,Jennings LK,Zhang XA .2011 .Tetraspanins and tumour progression. Clin Exp Metastasis, 10(3) : 261-70.
Pacienza N,Yannarelli G. .2019 .CD9: A possible clue into breast cancer chemoresistance. Oncotarget, 10(47) : 4921-3.
Kulis J,Wawrowski L,Sedek L,Wrobel L,Slota L,van der Velden VHJ .2022 .Machine learning based analysis of relations between antigen expression and genetic aberrations in childhood B-cell precursor acute lymphoblastic leukaemia. J Clin Med, 10(9) : 2281.
Kulis J,Sedek L,Slota L,Perkowski B,Szczepanski T. .2022 .Commonly assessed markers in childhood BCP-ALL diagnostic panels and their association with genetic aberrations and outcome prediction. Genes (Basel), 10(8) : 1374.
Swerdlow SH,Campo E,Harris NL,Pileri ES,Stein SA,H SA .2008 .Classi cation_of_Tumours_of_the_Haematopoietic_. , : .
Koh HM,Jang BG,Lee DH,Hyun CL .2021 .Increased CD9 expression predicts favorable prognosis in human cancers: A systematic review and meta-analysis. Cancer Cell Int, 10(1) : 472.
Sahar M,Gul S,Shehzad F,Mohsin S. .2020 .Demographic features of pediatric B-ALL (B lineage acute lymphoblastic leukaemia) patients in Pakistani population. Prof Med J, 10(8) : 1582-9.
Touzet L,Dumezy F,Roumier C,Berthon C,Bories C,Quesnel B .2007 .CD9 in acute myeloid leukaemia: Prognostic role and usefulness to target leukemic stem cells. Cancer Med, 10(3) : 1279-88.
Wang W,Gao L,Li Y,Li ZL,Gong M,Huang FZ .2015 .The application of CD73 in minimal residual disease monitoring using ow cytometry in B-cell acute lymphoblastic leuka-emia. Leuk Lymphoma, 1070153(5) : 1174-81.
Gupta DG,Varma N,Naseem S,Sachdeva MUS,Bose P,Binota J .2021 .Characterisation of immunophenotypic aberrancies with respect to common fusion transcripts in B-cell precursor acute lymphoblastic leukaemia: A report of 986 Indian patients. Turk J Haematol, 0326(1) : 1-2.
Leung KT,Zhang C,Chan KYY,Li K,Cheung JTK,Ng MHL .2020 .CD9 blockade suppresses disease progression of high- risk pediatric B-cell precursor acute lymphoblastic leukaemia and enhances chemosensitivity. Leukemia, 10(3) : 709-20.
Abdulateef NAB,Ismail MM,Aljedani H. .2014 .Clinical signi - cance of co-expression of aberrant antigens in acute leukaemia: A retrospective cohort study in Makah Al Mukaramah, Saudi Arabia. Asian Pac J Cancer Prev, 15(1) : 221-7.
Esh SS,Azizi NMA,Elsafy U,Sherief LM,Zakaria M,Abdalah MM .2017 .Can CD34/CD123 distinguish between normal and leukemic B-cell precursors?. Egypt J Haematol, 10(4) : 17-60.
Leung KT,Cai J,Liu Y,Chan KYY,Shao J,Yang H .2024 .Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: Insights from a nationwide multicenter study in China. Leukemia, 10(1) : 1-8.
0

Citations

0

Downloads

90

Views